1235587-46-8

Upstream product

• 97980-71-7 2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetic acid 
• 454170-83-3 C₁₆H₁₄N₂O₄ 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 104-54-1 3-Phenylpropenol 
• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 123-08-0 4-hydroxy-benzaldehyde 
• 135733-30-1 3-(hydroxymethyl)-4-phenylfuroxan 
• 84212-46-4 ethyl 2-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetate 
• 217966-10-4 3-chloromethyl-4-phenyl-1,2,5-oxadiazole N²-oxide 

Downstream Products

• 1245644-41-0 O₅-acetyl-O₇-chrysinacetic acid [4-(4-phenyl-1,2,5-oxadiazole-2-oxide-3-yl)methoxyl]benzyl ester 

Relevant academic research and scientific papers

Furoxan nitric oxide donor coupled chrysin derivatives: Synthesis and vasculoprotection

A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of l-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.